Log In
Print
BCIQ
Print
Print this Print this
 

VK0612 (formerly MB07803)

  Manage Alerts
Collapse Summary General Information
Company Ligand Pharmaceuticals Inc.
DescriptionFructose 1,6-bisphosphatase inhibitor
Molecular Target Fructose 1,6-bisphosphatase
Mechanism of ActionFructose 1,6-bisphosphatase inhibitor
Therapeutic Modality 
Latest Stage of DevelopmentPhase II
Standard IndicationDiabetes
Indication DetailsTreat Type II diabetes
Regulatory Designation

Partner

Viking Therapeutics Inc.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today